Dupixent surges while EYLEA HD defends the eye franchise
- Dupixent global sales hit a record $6.5 billion in Q3 2026.
- EYLEA HD sales reached $700 million, capturing two thirds of the United States retina franchise.
- Regeneron recorded its full share of Sanofi profits for the first time in Q3.
- Management expects an FDA decision on the EYLEA HD pre-filled syringe by year end.
- Finn sees strong financial health balancing questions about the clinical pipeline.
A stronger core, a thinner pipeline
Regeneron is firing on its main cylinders. Dupixent, sold with Sanofi, reached $6.5 billion in global Q3 2026 net sales and grew 35 percent on a constant currency basis. The company also fully repaid its Sanofi development balance earlier in the year, which allowed it to record a full share of collaboration profits for the first time this quarter.
The United States eye franchise is successfully transitioning. EYLEA HD generated $700 million in Q3 2026, growing 62 percent from a year ago. This newer drug now accounts for nearly two thirds of the United States retinal franchise, helping the company hold its ground even as older EYLEA sales fall against heavy competition.
However, challenges remain. The FDA delayed its decision on a pre-filled syringe for EYLEA HD to the end of 2026, which keeps a key defense tool out of doctors' hands. Multiple new 2-mg biosimilars are expected to launch in late 2026, which will test how well the combined eye franchise can maintain growth.
Following a melanoma trial failure earlier in the year, the clinical pipeline has fewer near-term catalysts. The stock story relies on Dupixent growing even larger, EYLEA HD fending off new rivals, and upcoming data for drugs like cemdisiran proving the pipeline can still deliver.
Science, sales, and partners
Regeneron is a fully integrated biotech company. That means it discovers drugs, tests them, makes them, and sells some of them itself. Its research engine uses antibody discovery tools to create new drug candidates.
Money comes from two main places. First, Regeneron records direct product sales in the United States for drugs like EYLEA, EYLEA HD, Libtayo, and Praluent. In Q3 2026, combined United States sales for the EYLEA franchise were $1.1 billion.
Second, Regeneron earns collaboration revenue from partners. Sanofi is the most important partner because it records Dupixent sales globally and shares profits with Regeneron. Bayer records EYLEA sales outside the United States and shares profits.
This model works when the science keeps producing big products and partners sell them well. It breaks when a key drug faces biosimilars, when a trial fails, or when a contract manufacturer delays an important product form.
The drugs that matter
Dupixent
Dupixent treats allergic and inflammatory diseases. Sanofi records sales, while Regeneron earns its share of the profits.
EYLEA HD and EYLEA
These eye drugs treat diseases such as wet age-related macular degeneration. EYLEA HD is now the larger seller in the United States, replacing the declining legacy product.
Libtayo
Libtayo is a cancer drug used in non-small cell lung cancer and other settings. Regeneron records global net product sales, which reached $550 million in Q3 2026.
Praluent
Praluent lowers LDL cholesterol. Regeneron handles the United States market, while Sanofi handles sales outside the United States and pays Regeneron royalties.
Cemdisiran
This is a pipeline asset targeting myasthenia gravis. The company expects an FDA decision on its application in November 2026.
Revenue split, not operating segments
Regeneron reports one operating segment. The mix below reflects recent historical revenue trends, showing where money comes from rather than separate business units.
What could go wrong
Dupixent concentration
High impact · Medium oddsThe bull case leans heavily on Dupixent. It is growing quickly, but any slowdown would be felt across the whole company. Regeneron's Sanofi collaboration revenue is its largest growth engine.
EYLEA biosimilar wave
High impact · High oddsMultiple 2-mg biosimilars are expected to launch in the second half of 2026. Legacy EYLEA is falling rapidly, and these new rivals will test whether EYLEA HD can defend the total franchise.
Pre-filled syringe delay
Medium impact · Medium oddsThe FDA delayed its decision on the EYLEA HD pre-filled syringe past the originally expected date. The company now hopes for approval by year end 2026. A pre-filled syringe is needed to make the drug easier for doctors to use.
Pipeline gap
High impact · Medium oddsThe melanoma study failure earlier this year removed a major near-term catalyst. The company needs other pipeline drugs to prove they can become the next major growth driver.
In one breath
Why is Dupixent so important to Regeneron?
Dupixent is Regeneron's main growth driver through its Sanofi partnership. In Q3 2026, global Dupixent net sales reached $6.5 billion and grew 35 percent.
What is happening to EYLEA?
EYLEA HD is growing rapidly and replacing the older version. In Q3 2026, EYLEA HD United States sales were $700 million, while legacy EYLEA continued to decline under competitive pressure.
What is the Sanofi collaboration?
Regeneron partners with Sanofi to sell drugs like Dupixent globally. They split the profits, and recently expanded the alliance to share profits equally on four next-generation antibodies.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Regeneron Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

